Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
Status:
Active, not recruiting
Trial end date:
2026-12-04
Target enrollment:
Participant gender:
Summary
This is a phase 1 study to evaluate investigational drug RP-6306 in combination with
carboplatin and paclitaxel in patients with TP53 mutated ovarian or uterine cancer. The dose
escalation part of the study will determine the maximum tolerated dose (MTD) and recommended
Phase 2 Dose (RP2D) and schedule of RP-6306 in combination with carboplatin and paclitaxel
and the dose expansion will further assess the safety and tolerability as well as determine
the preliminary efficacy of RP-6306 in combination with carboplatin and paclitaxel.